Roche Collaborates with Merck on Developmental Test for Cancer-Related Gene Mutation
News Feb 19, 2010
Roche Molecular Systems, Inc. has announced a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Merck access to Roche's developmental microarray-based AmpliChip p53 Test, which is designed to detect mutations in the tumor suppressor gene p53.
By identifying cancers that harbor a dysfunctional p53 gene, the companies aim to achieve better treatment outcomes in cancer patients by determining which patients are most likely to respond to certain investigational therapeutic candidates.
"Roche designed its investigational AmpliChip p53 Test to rapidly provide clinically important information that can be used early in pharmaceutical development to help predict cancer patient responses to certain therapeutic candidates," said Paul Brown, president and CEO, Roche Molecular Diagnostics. "Roche is excited to enter into this collaboration with Merck because of the potential this test has to improve cancer patient response to treatment."
The p53 protein is a critical component of normal cell response to various stress types including damaged genetic material or DNA (deoxyribonucleic acid). The p53 protein functions by activating DNA repair proteins, inducing growth arrest for repair of DNA damage, and by initiating apoptosis (programmed cell death) in the case of irreparable DNA damage. When p53 function is deficient, a cell's response to DNA damage is severely impaired, contributing to tumor growth and increasing tumor cells' resistance to chemotherapy. Roche's investigational AmpliChip p53 Test is designed to detect damage to p53 DNA in tumor cells in order to identify which cells carry dysfunctional p53 proteins that can lead to treatment resistance.
"The goal of our research is to discover and develop innovative cancer therapeutics and deliver them to the right patients at the right time," said Eric Rubin, M.D., vice president, Oncology, Merck Research Laboratories. "By applying the AmpliChip p53 Test in selected clinical trials we hope to identify those patients most likely to respond to specific therapeutic regimens in development."
Automated Robotic Device Enables Faster Blood TestingNews
Rutgers researchers have created an automated blood drawing and testing device that provides rapid results, potentially improving the workflow in hospitals and other health-related institutions to allow health care practitioners to spend more time treating patients.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018